Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Predictors and Therapeutic Gaps in CKM Syndrome Among Adults With Type 2 Diabetes
Sponsor: Assiut University
Summary
Type 2 diabetes (T2D) is a principal driver of cardiovascular-renal-metabolic (CKM) syndrome, where metabolic, renal, and cardiac dysfunction accelerate disease progression. This cross-sectional study aims to classify adult patients with T2D attending outpatient clinics at Assiut University Hospitals across CKM stages (0-4) according to the 2023 American Heart Association (AHA) staging system. Additionally, the study identifies independent clinical and laboratory predictors of advanced CKM stages (Stages 3-4) and quantifies the therapeutic gap regarding guideline-indicated organ-protective medications (SGLT2 inhibitors, GLP-1 receptor agonists, RAAS inhibitors, statins, and MRAs).
Official title: Clinical Predictors and Therapeutic Gaps Across Stages of Cardio-Renal-Metabolic (CKM) Syndrome Among Adults With Type 2 Diabetes: A Cross-Sectional Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
231
Start Date
2026-10-20
Completion Date
2028-07-10
Last Updated
2026-10-02
Healthy Volunteers
No
Interventions
clinical and laboratory CKM staging evaluation
Comprehensive single-visit assessment including clinical examination (BP, BMI, waist circumference, 12-lead ECG), routine laboratory testing (fasting blood glucose, HbA1c, lipid profile, serum creatinine/eGFR, spot urine albumin-to-creatinine ratio, serum potassium), abdominal ultrasound, and echocardiography to classify CKM syndrome stage (0-4) per AHA 2023 criteria and evaluate current prescribing patterns of organ-protective therapies\[span\_1\](start\_span)\[span\_1\](end\_span).
Locations (1)
Assiut university
Asyut, Abutig, Egypt